MedTrace Logo

Long-term Safety Trial with NVDX3

NCT06532253 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-09-05

No results posted yet for this study

Summary

An study evaluating the long-term safety of all patients previously treated with NVDX3.

Conditions

  • Distal Radius Fractures
  • Degenerative Lumbar Spondylolisthesis

Interventions

DRUG

NVDX3

NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)

Sponsors & Collaborators

  • PrimeVigilance

    collaborator INDUSTRY

  • Data Investigation Company Europe (DICE)

    collaborator UNKNOWN

  • Novadip Biosciences

    lead INDUSTRY

Principal Investigators

  • Torsten Gerich, MD · Centre Hospitalier du Luxembourg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-22
Primary Completion
2036-03-31
Completion
2036-03-31

Countries

  • Luxembourg

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06532253 on ClinicalTrials.gov